Structural basis for activation of trimeric Gi proteins by multiple growth factor receptors via GIV/Girdin

  • Mol Biol Cell. 2014 Nov 5;25(22):3654-71. doi: 10.1091/mbc.E14-05-0978.
Changsheng Lin  1 Jason Ear  1 Krishna Midde  1 Inmaculada Lopez-Sanchez  1 Nicolas Aznar  1 Mikel Garcia-Marcos  2 Irina Kufareva  3 Ruben Abagyan  3 Pradipta Ghosh  4
Affiliations
  • 1. Department of Medicine, University of California, San Diego, School of Medicine, CA 92093.
  • 2. Department of Cellular and Molecular Medicine, University of California, San Diego, School of Medicine, CA 92093.
  • 3. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093.
  • 4. Department of Medicine, University of California, San Diego, School of Medicine, CA 92093 [email protected].
Abstract

A long-standing issue in the field of signal transduction is to understand the cross-talk between Receptor Tyrosine Kinases (RTKs) and heterotrimeric G proteins, two major and distinct signaling hubs that control eukaryotic cell behavior. Although stimulation of many RTKs leads to activation of trimeric G proteins, the molecular mechanisms behind this phenomenon remain elusive. We discovered a unifying mechanism that allows GIV/Girdin, a bona fide metastasis-related protein and a guanine-nucleotide exchange factor (GEF) for Gαi, to serve as a direct platform for multiple RTKs to activate Gαi proteins. Using a combination of homology modeling, protein-protein interaction, and kinase assays, we demonstrate that a stretch of ∼110 Amino acids within GIV C-terminus displays structural plasticity that allows folding into a SH2-like domain in the presence of phosphotyrosine ligands. Using protein-protein interaction assays, we demonstrated that both SH2 and GEF domains of GIV are required for the formation of a ligand-activated ternary complex between GIV, Gαi, and growth factor receptors and for activation of Gαi after growth factor stimulation. Expression of a SH2-deficient GIV mutant (Arg 1745→Leu) that cannot bind RTKs impaired all previously demonstrated functions of GIV-Akt enhancement, actin remodeling, and cell migration. The mechanistic and structural insights gained here shed light on the long-standing questions surrounding RTK/G protein cross-talk, set a novel paradigm, and characterize a unique pharmacological target for uncoupling GIV-dependent signaling downstream of multiple oncogenic RTKs.